Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate

被引：0
|
作者：
Cosman, F. [1 ]
Wermers, R. A. [2 ]
Recknor, C. [3 ]
Mauck, K. F. [2 ]
Xie, L. [4 ]
Glass, E. V. [4 ]
Krege, J. H. [4 ]
机构：
[1] Helen Hayes Hosp, Clin Res Ctr, W Haverstraw, NY USA
[2] Mayo Clin, Rochester, MN 55905 USA
[3] United Osteoporosis Ctr, Gainesville, FL 32601 USA
[4] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
CALCIFIED TISSUE INTERNATIONAL | 2008年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [21] REDUCTION IN BACK PAIN FOLLOWING TERIPARATIDE COMPARED WITH ALENDRONATE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Dore, R. K.
    Krege, J. H.
    Chen, P.
    Glass, E. V.
    Martin, J. San
    Miller, P. D.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2004, 74 : S89 - S89
  • [22] Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice
    Ish-Shalom, Sophia
    Dumitrache, Constantin
    El-Husseini, Timour Fikry
    Hussein, Azza
    Barker, Clare
    Pavo, Imre
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (02) : 343 - 353
  • [23] Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis
    Sanad, Z.
    Ellakwa, H.
    Desouky, B.
    [J]. CLIMACTERIC, 2011, 14 (03) : 369 - 377
  • [24] Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis
    S. Adami
    J. San Martin
    M. Muñoz-Torres
    M. J. Econs
    L. Xie
    G. P. Dalsky
    M. McClung
    D. Felsenberg
    J. P. Brown
    M. L. Brandi
    A. Sipos
    [J]. Osteoporosis International, 2008, 19 : 87 - 94
  • [25] Teriparatide versus alendronate in glucocorticoid-induced osteoporosis: Results of a subgroup analysis in men, pre- and postmenopausal women
    Langdahl, B.
    Dobnig, H.
    Zanchetta, J. R.
    Maricic, M.
    Krohn, K.
    See, K.
    Marin, F.
    Warner, M. R.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S251 - S251
  • [26] Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate
    Miller, PD
    Shergy, WJ
    Body, JJ
    Chen, PQ
    Rohe, ME
    Krege, JH
    [J]. JOURNAL OF RHEUMATOLOGY, 2005, 32 (08) : 1556 - 1562
  • [27] Femoral strength in osteoporotic women treated with teriparatide or alendronate
    Keaveny, Tony M.
    McClung, Michael R.
    Wan, Xiaohai
    Kopperdahl, David L.
    Mitlak, Bruce H.
    Krohn, Kelly
    [J]. BONE, 2012, 50 (01) : 165 - 170
  • [28] Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis
    Kong, Meng
    Gao, Changtong
    Luan, Xiaona
    Fan, Cuiying
    Hao, Meng
    Jin, Canghai
    Zhao, Jiangning
    Li, Hongyan
    Zhao, Jindong
    Luan, Jian
    Lin, Yong
    Li, Qiang
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2024, 25 (01)
  • [29] Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
    J. J. Stepan
    D. B. Burr
    J. Li
    Y. L. Ma
    H. Petto
    A. Sipos
    H. Dobnig
    A. Fahrleitner-Pammer
    D. Michalská
    I. Pavo
    [J]. Osteoporosis International, 2010, 21 : 2027 - 2036
  • [30] EFFECT OF TERIPARATIDE IN CHINESE AND CAUCASIAN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: BRIDGING FINDINGS ON EFFICACY
    Li, M.
    Gurbuz, S.
    Chen, Y.
    Zhang, B.
    Li, Y. J.
    Chen, Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S216 - S216
12345